197 related articles for article (PubMed ID: 8285144)
1. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.
Hasinoff BB; Kala SV
Agents Actions; 1993 May; 39(1-2):72-81. PubMed ID: 8285144
[TBL] [Abstract][Full Text] [Related]
2. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
Hasinoff BB
Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
[TBL] [Abstract][Full Text] [Related]
3. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
Hasinoff BB
Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
[TBL] [Abstract][Full Text] [Related]
4. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
Hasinoff BB
Drug Metab Dispos; 1990; 18(3):344-9. PubMed ID: 1974197
[TBL] [Abstract][Full Text] [Related]
5. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.
Buss JL; Hasinoff BB
Agents Actions; 1993 Sep; 40(1-2):86-95. PubMed ID: 8147274
[TBL] [Abstract][Full Text] [Related]
6. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).
Hasinoff BB
Free Radic Res; 1995 Apr; 22(4):319-25. PubMed ID: 7633562
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
Hasinoff BB
J Pharm Sci; 1994 Jan; 83(1):64-7. PubMed ID: 8138912
[TBL] [Abstract][Full Text] [Related]
8. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
Diop NK; Vitellaro LK; Arnold P; Shang M; Marusak RA
J Inorg Biochem; 2000 Feb; 78(3):209-16. PubMed ID: 10805177
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Malisza KL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
[TBL] [Abstract][Full Text] [Related]
10. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
Hasinoff BB; Reinders FX; Clark V
Drug Metab Dispos; 1991; 19(1):74-80. PubMed ID: 1673425
[TBL] [Abstract][Full Text] [Related]
11. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Thomas C; Vile GF; Winterbourn CC
Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
[TBL] [Abstract][Full Text] [Related]
12. Chemistry of dexrazoxane and analogues.
Hasinoff BB
Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
[TBL] [Abstract][Full Text] [Related]
13. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
14. Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187).
Schroeder PE; Davidson JN; Hasinoff BB
Drug Metab Dispos; 2002 Dec; 30(12):1431-5. PubMed ID: 12433815
[TBL] [Abstract][Full Text] [Related]
15. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187).
Buss JL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 317(1):121-7. PubMed ID: 7872773
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Schroeder PE; Hasinoff BB
Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
Hasinoff BB
Drug Metab Dispos; 1993; 21(5):883-8. PubMed ID: 7902252
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane).
Malisza KL; Hasinoff BB
Redox Rep; 1996 Feb; 2(1):69-73. PubMed ID: 27414516
[TBL] [Abstract][Full Text] [Related]
20. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
Vile GF; Winterbourn CC
Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
